Frontmatter -- List of first-mentioned contributors -- Contents -- Introduction / Meyer, H. -- I. New aspects in diabetes mellitus -- The epidemiology of diabetes mellitus and its relationship with cardiovascular disease / Zimmet, P. / Serjeantson, S. -- Syndrome X: fact or fiction? / Lebovitz, H. E. -- Strategies for the treatment of hyperglycemia in Syndrome X / Josse, R. G. -- Treatment strategies of Syndrome X — hypertension and vascular complications / Litbell, H. -- Lipid metabolism: metabolic consequences of moderate hypertriglyceridemia / Vega, G. L. -- Update on the treatment of NIDDM / Lefèbvre, P. J. / Sebeen, A. J. -- Hyperinsulinemia and macrovascular complications in NIDDM / Standi, E. / Janka, H. U. / Stiegler, H. / Mehnert, H. -- II. Quality of life in diabetes mellitus -- Diabetes and quality of life: some current issues in definition and research / Croog, S. H. -- Quality of life in patients with type II diabetes mellitus / Waadt, S. / Duran, G. / Waadt, M. / Herschbach, P. / Strian, F. -- Well-being in non-insulin-dependent diabetic patients (NIDDM) - a long-term follow-up / Toeller, M. -- III. Studies with acarbose -- Acarbose monotherapy in non-insulin-dependent diabetes mellitus — the German experience / Hanefeld, M. -- Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet / Willms, B. -- Clinical efficacy of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus (NIDDM) — a placebo-controlled double-blind comparative study / Goto, Yuichiro / Goto, Yosbio / Nakagawa, S. / Orimo, H. / Ikeda, Y. / Sakamoto, N. / Fukui, I. / Tarui, S. / Baba, S. / Kaneko, T. / Mimura, G. -- Effects of long-term administration of acarbose in patients with NIDDM - a double-blind study with placebo / Sakamoto, N. / Hotta, N. / Koh, N. / Sakakibara, F. / Haga, T. / Kobayashi, M. / Kakuta, H. / Sano, T. / Yamada, H. / Matsumae, H. / Kitazawa, S. -- Effects of acarbose on blood glucose control in insulindependent diabetes mellitus / Ikeda, Y. / Tsuruoka, A. / Izumi, K. / Yoshida, M. / Nakata, Y. / Omori, Y. / Sanaka, M. / Kitagawa, T. / Miyamoto, Y. / Fujita, H. / Kondo, M. / Sato, T. / Takeda, A. / Tanae, A. / Matsuoka, K. / Murakami, K. / Yamamoto, S. -- European experience in the treatment of IDDM with acarbose in combination with insulin / Raptis, S. A. -- Round table discussion on open questions and future aspects -- IV. Abstracts -- A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone / Coniff, R. F. -- A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) and sulfonylureas in the treatment of NIDDM inadequately controlled by maximal doses of sulfonylureas (SFU) / Coniff, R. F. / Innerfield, R. J. -- A multi-center, double-blind, comparative study of the long-term efficacy and safety of acarbose (BAY g 5421) vs. placebo in the treatment of patients with insulin requiring type II diabetes mellitus / Pi-Sunyer, F. X. -- Prospective, multi-center studies of the efficacy and safety of acarbose (BAY g 5421) in the treatment of type I diabetes mellitus / Schade, D. S. -- Two multi-center, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes / Holander, P. / Coniff, R. F. -- Clinical study of reduced postprandial hyperglycemia by acarbose and glycemic impact of fructose and sucrose in insulin therapy / Wernecke, J. / Dreyer, M. / Fisch, R. / Michels, G. / Lührs, M. / Dammann, H. G. -- 6 months monotherapy of NIDDM with acarbose or glibenclamide / Spengler, M. / Hänsel, G. / Boehme, K. -- Decreased insulin requirement and postprandial insulin plasma concentrations under treatment with the a-glucosidase inhibitor acarbose / Hobler, H. / Spengler, M. -- Long-term treatment of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus / Goto, Yoshio / Toyota, T. / Oikawa, S. / Maruhama, Y. / Tamura, M. / Komatsu, K. / Fujiya, H. / Abe, R. / Kikuchi, H. -- Clinical efficacy and tolerability of acarbose in IDDM treatment / de la Calle, H. / Escobar, F. / Figuerola, D. / Gil, E. / Herrera-Pombo, J. L. / Jiménez, A. / de Leiva, A. / Pallardo, L. F. / Piñón, F. / Soler, J. / Tebar, J. / Vázquez, V. A. -- Effects of acarbose on the glycemic index of different foods / Calle, A. / Rodriguez, C. / Gil, E. -- Effects of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in type II diabetics / Rohr, G. / Schmidt, I. / Schwedes, U. / Usadel, K. H. / Norenberg, Chr. / Spengler, M. -- Influence of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in healthy volunteers / Rosak, C. / Boehm, B. O. / Althoff, P. H. / Hobler, H. / Boehme, K. -- Acarbose: an intestinal tract a-glucosidase inhibitor — pharmacological effects on insulin and glycemia in response to a sucrose load / Tawara, K. / Mochizuki, N. / Donkai, A. / Hikima, Y. -- Assessment of efficacy and tolerability of acarbose (Glucobay®) by clinical data pool / Spengler, M. / Cagatay, M. -- Long-term tolerability of acarbose / Spengler, M. / Hobler, H. / Cagatay, M. -- Assessment of efficacy and tolerability of acarbose in diabetic patients 5 — 16 years of age / Spengler, M. / Cagatay, M. -- Effect of acarbose repeated dosing on antipyrine test in healthy volunteers / Pinquier, J. L. / Pello, J. Y. / Key, E. / De Lauture, D. / D’Athis, P. / Strauch, G. / Olive, G. / Mover, I. / Prunieras, F. -- Discussionweiterlesen